Intended for healthcare professionals


Western medicine: a confidence trick driven by the drug industry?

BMJ 2002; 325 doi: (Published 03 August 2002) Cite this as: BMJ 2002;325:h

A touch of hypocrisy?

Much of the time,various commercial approaches of promoting products
can be challenged on a number of different grounds. If the product itself
is a potential health risk to the consumer, then not only the manufacturer
concerned should be liable, but also the relevant licensing organisations,
and those who promote such products in a most public manner. In this
respect,I wonder as to how much blame the BMJ and BMA would accept for the
increasing drug advertisements which they propagate via their paper and
online journals; has the BMA's/BMJ's commercial eargerness brought a too
cosy a relationship with the pharmaceutical sector?. Further,the recent
appointment of Jeremy Strachan to the post of Secretary of the BMA (who
was previously with GlaxoSmithKline--a company referred to in the Editor's
Choice),goes on to show with whom it likes partnerships.

The editor had indicated that the BMJ hopes to publish an editorial
next week, in realtion to the recent High Court judgment in respect of the
third-generation pill case.Those who are interested, may view that full
judgment by following:
[accessd 04 August 2002]

This may also be an opportune moment for all BMA officers &
officials to declare any financial/commercial interests that they have in
pharmaceutical companies,rather than awaiting other modes of scrutiny
which might be embarrassing to the BMA as a trade union, and for the
individuals concerned.

Competing interests: No competing interests

05 August 2002
Jay Ilangaratne